0 CHECKOUT

Febrile Neutropenia - Pipeline Review, H1 2015

  • ID: 3259638
  • April 2015
  • 51 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Apotex, Inc.
  • Biocon Limited
  • Coherus BioSciences, Inc.
  • Pfizer Inc.
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • MORE

Febrile Neutropenia - Pipeline Review, H1 2015

Summary

This, ‘Febrile Neutropenia - Pipeline Review, H1 2015’, provides an overview of the Febrile Neutropenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Febrile Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Febrile Neutropenia and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Apotex, Inc.
  • Biocon Limited
  • Coherus BioSciences, Inc.
  • Pfizer Inc.
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Febrile Neutropenia Overview
Therapeutics Development
Pipeline Products for Febrile Neutropenia - Overview
Pipeline Products for Febrile Neutropenia - Comparative Analysis
Febrile Neutropenia - Therapeutics under Development by Companies
Febrile Neutropenia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Febrile Neutropenia - Products under Development by Companies
Febrile Neutropenia - Companies Involved in Therapeutics Development
Apotex, Inc.
Biocon Limited
Coherus BioSciences, Inc.
Pfizer Inc.
Richter Gedeon Nyrt.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Therapeutic Proteins International, LLC
Xenetic Biosciences plc
Febrile Neutropenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(piperacillin sodium + tazobactam sodium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lipegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stimuxen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Febrile Neutropenia - Recent Pipeline Updates
Febrile Neutropenia - Product Development Milestones
Featured News & Press Releases
Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
Jul 02, 2014: Application for the Additional Indication of Febrile Neutropenia for ZOSYN, an Injectable Antibiotic Combined with ß-Lactamase Inhibitor
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Febrile Neutropenia, H1 2015
Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Febrile Neutropenia - Pipeline by Apotex, Inc., H1 2015
Febrile Neutropenia - Pipeline by Biocon Limited, H1 2015
Febrile Neutropenia - Pipeline by Coherus BioSciences, Inc., H1 2015
Febrile Neutropenia - Pipeline by Pfizer Inc., H1 2015
Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2015
Febrile Neutropenia - Pipeline by Sandoz International GmbH, H1 2015
Febrile Neutropenia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Febrile Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H1 2015
Febrile Neutropenia - Pipeline by Xenetic Biosciences plc, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Febrile Neutropenia Therapeutics - Recent Pipeline Updates, H1 2015

List of Figures
Number of Products under Development for Febrile Neutropenia, H1 2015
Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Apotex, Inc.
Biocon Limited
Coherus BioSciences, Inc.
Pfizer Inc.
Richter Gedeon Nyrt.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Therapeutic Proteins International, LLC
Xenetic Biosciences plc

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.